This combined approach supports long-term weight management by fostering healthier habits and coping strategies
Triple agonists including retatrutide show exceptional promise based on remarkable weight loss and liver fat normalization in early trials, with dedicated MASH histology studies ongoing
It's important to acknowledge that these are common, with studies indicating that a significant percentage of users (reports range from 40% up to 85%) experience issues like nausea, vomiting, diarrhea, constipation, bloating, or heartburn, particularly when first starting the medication or increasing the dose
however, NHS access for weight management depends on NICE guidance and local commissioning decisions, and availability varies
see the EMC SmPC and NHS Mounjaro page [14] Patients are encouraged to discuss their options with a GP, who can refer to tier 2, tier 3, or tier 4 specialist weight management services as appropriate (in line with NICE CG189 and local commissioning arrangements)
What many people dont realize, however, is that the body already produces GLP-1 naturally
